Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 3 4 2020
medline: 3 4 2020
entrez: 3 4 2020
Statut: ppublish

Résumé

An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiants

DOI: 10.1038/s41586-020-2155-6 PMID: 32238929
pubmed: 32238929
doi: 10.1038/s41586-020-2155-6
pii: 10.1038/s41586-020-2155-6
doi:

Types de publication

Journal Article Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

E1

Commentaires et corrections

Type : ErratumFor

Auteurs

Rita Cabrita (R)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Martin Lauss (M)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Adriana Sanna (A)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Marco Donia (M)

National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.

Mathilde Skaarup Larsen (M)

Department of Clinical Pathology, Herlev University Hospital, Herlev, Denmark.

Shamik Mitra (S)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Iva Johansson (I)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Bengt Phung (B)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Katja Harbst (K)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Johan Vallon-Christersson (J)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Alison van Schoiack (A)

NanoString Technologies, Seattle, WA, USA.

Kristina Lövgren (K)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Sarah Warren (S)

NanoString Technologies, Seattle, WA, USA.

Karin Jirström (K)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Håkan Olsson (H)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.

Kristian Pietras (K)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Center, Lund University, Lund, Sweden.

Christian Ingvar (C)

Department of Surgery, Skåne University Hospital, Lund, Sweden.

Karolin Isaksson (K)

Department of Surgery, Skåne University Hospital, Lund, Sweden.

Dirk Schadendorf (D)

Department of Dermatology, University Hospital of Essen, Essen, Germany.

Henrik Schmidt (H)

Department of Oncology, Århus University Hospital, Aarhus, Denmark.

Lars Bastholt (L)

Department of Oncology, Odense University Hospital, Odense, Denmark.

Ana Carneiro (A)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Department of Oncology, Skåne University Hospital, Lund, Sweden.

Jennifer A Wargo (JA)

Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Inge Marie Svane (IM)

National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.

Göran Jönsson (G)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden. goran_b.jonsson@med.lu.se.

Classifications MeSH